Cardax (Cardax) Issuance of Stock : $0.00 Mil (TTM As of Mar. 2021)

View and export this data going back to 2012. Start your Free Trial

What is Cardax Issuance of Stock?

Cardax's Issuance of Stock for the three months ended in Mar. 2021 was $0.00 Mil.

Cardax's Issuance of Stock for the trailing twelve months (TTM) ended in Mar. 2021 was $0.00 Mil.

Cardax Issuance of Stock Historical Data

The historical data trend for Cardax's Issuance of Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardax Issuance of Stock Chart

Cardax Annual Data

Trend

Mar12

Mar13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Issuance of Stock

Get a 7-Day Free Trial

1.12

4.14

1.24

0.25

Cardax Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
Issuance of Stock	Get a 7-Day Free Trial															-	-	-	-	-

Cardax Issuance of Stock Calculation

A company may raise cash from issuing new shares. Issuance of Stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Issuance of Stock for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Cardax Issuance of Stock Related Terms

Thank you for viewing the detailed overview of Cardax's Issuance of Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Cardax (Cardax) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardax Inc (OTCPK:CDXI) » Definitions » Issuance of Stock

Comparable Companies

IMUN BOM:506365 PPCB HSTC XCNQ:NSHS RSPI BOM:542910 BOM:539206 RBSH GNBT

Traded in Other Exchanges

N/A

Address

2800 Woodlawn Drive, Suite 129, Honolulu, HI, USA, 96822

Website

http://www.cardaxpharma.com

Cardax Inc is a life sciences company engaged in the development of marketing, and distribution of consumer health products in the United States. The firm's platform has applications in arthritis, metabolic syndrome, liver disease, and cardiovascular disease, as well as macular degeneration and prostate disease. It is focused on the development of astaxanthin technologies. The group's product ZanthoSyn is marketed as a novel astaxanthin dietary supplement. Astaxanthin is a clinically studied ingredient with a safe anti-inflammatory activity that supports joint health, cardiovascular health, metabolic health, and liver health. Geographically, it generates maximum revenue from the United States.

Executives

Paulson Capital Corp	10 percent owner	222 THIRD STREET, SUITE 2241, CAMBRIDGE MA 02142
Paulson Investment Company, Inc.	10 percent owner	5335 MEADOWS ROAD SUITE 465 LAKE OSWEGO OR 97035
Paulson Cardax Investments 1 Llc	10 percent owner	811 SW NAITO PKWY SUITE 300 PORTLAND OR 97204